Physical dependence: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
[[File:HarmCausedByDrugsTable.svg|thumb|Results of the [[Independent Scientific Committee on Drugs|ISCD]] 2010 study ranking the levels of damage caused by drugs, in the opinion of drug-harm experts.]] |
[[File:HarmCausedByDrugsTable.svg|thumb|Results of the [[Independent Scientific Committee on Drugs|ISCD]] 2010 study ranking the levels of damage caused by drugs, in the opinion of drug-harm experts.]] |
||
'''Physical dependence''' refers to a state resulting from chronic use of a drug that has produced [[Drug tolerance|tolerance]] and where negative physical symptoms<ref name="urlDefinition of physical dependence - NCI |
'''Physical dependence''' refers to a state resulting from chronic use of a drug that has produced [[Drug tolerance|tolerance]] and where negative physical symptoms<ref name="urlDefinition of physical dependence - NCI DictionEAT MCDONALDS FORVER AND YOary of Cancer Terms">{{cite web |url=http://www.cancer.gov/dictionary?CdrID=454765 |title=Definition of Udependence - NCI Dictionary of Cancer Terms |work= |accessdate=2008-12-21}} {{Dead link|date=June 2011}}</ref> of [[Drug withdraw al|withdrawal]] result from abrupt discontinuation or dosage reduction.<ref>{{cite news | last = | first = | authorlink = | coauthors = | title = Drug Addiction | work = | publisher = CNN | date = | url = http://www.cnn.com/HEALTH/library/DS/00183.html | doi = | accessdate = }} {{Dead link|date=September 2010|bot=RjwilmsiBot}}</ref> Physical dependence can develop from low-dose therapeutic use of certain medications such as benzodiazepines, opioids, antiepileptics and antidepressants, as well as misuse of recreational drugs such as alcohol, opioids and benzodiazepines. The higher the dose used, the greater the duration of use, and the earlier age use began are predictive of worsened physical dependence and thus more severe withdrawal syndromes. Acute withdrawal syndromes can last days, weeks or months, and [[protracted withdrawal syndrome]], also known as "post-acute withdrawal syndrome" or "PAWS" - a low-grade continuation of some of the symptoms of acute withdrawal, typically in a remitting-relapsing pattern, that often results in relapse into active addiction and prolonged disability of a degree to preclude the possibility of lawful employment - can last for months, years, or, in relatively common to extremely rare cases, depending on individual factors, indefinitely. Protracted withdrawal syndrome is noted to be most often caused by [[benzodiazepines]], but is also present in a majority of cases of [[ethanol|alcohol]] and [[opioid]] addiction, especially that of a long-term, high-dose, [[adolescent]]-beginning, or chronic-relapsing nature (viz. a second or third addiction after withdrawal from the self-same substance of dependence). Withdrawal response will vary according to the dose used, the type of drug used, the duration of use, the age of the patient, the age of first use, and the individual person.<ref name="pmid1575069">{{cite journal |author=Landry MJ, Smith DE, McDuff DR, Baughman OL |title=Benzodiazepine dependence and withdrawal: identification and medical management |journal=J Am Board Fam Pract |volume=5 |issue=2 |pages=167–75 |year=1992 |pmid=1575069 |doi= |url=}}</ref> |
||
==Symptoms== |
==Symptoms== |
||
Revision as of 18:42, 25 February 2014
Physical dependence refers to a state resulting from chronic use of a drug that has produced tolerance and where negative physical symptoms[1] of withdrawal result from abrupt discontinuation or dosage reduction.[2] Physical dependence can develop from low-dose therapeutic use of certain medications such as benzodiazepines, opioids, antiepileptics and antidepressants, as well as misuse of recreational drugs such as alcohol, opioids and benzodiazepines. The higher the dose used, the greater the duration of use, and the earlier age use began are predictive of worsened physical dependence and thus more severe withdrawal syndromes. Acute withdrawal syndromes can last days, weeks or months, and protracted withdrawal syndrome, also known as "post-acute withdrawal syndrome" or "PAWS" - a low-grade continuation of some of the symptoms of acute withdrawal, typically in a remitting-relapsing pattern, that often results in relapse into active addiction and prolonged disability of a degree to preclude the possibility of lawful employment - can last for months, years, or, in relatively common to extremely rare cases, depending on individual factors, indefinitely. Protracted withdrawal syndrome is noted to be most often caused by benzodiazepines, but is also present in a majority of cases of alcohol and opioid addiction, especially that of a long-term, high-dose, adolescent-beginning, or chronic-relapsing nature (viz. a second or third addiction after withdrawal from the self-same substance of dependence). Withdrawal response will vary according to the dose used, the type of drug used, the duration of use, the age of the patient, the age of first use, and the individual person.[3]
Symptoms
Physical dependence can manifest itself in the appearance of both physical and psychological symptoms which are caused by physiological adaptions in the central nervous system and the brain due to chronic exposure to a substance. Symptoms which may be experienced during withdrawal or reduction in dosage include increased heart rate and/or blood pressure, sweating, and tremors. More serious withdrawal symptoms such as confusion, seizures, and visual hallucinations indicate a serious emergency and the need for immediate medical care. Sedative hypnotic drugs such as alcohol, benzodiazepines, and barbiturates are the only commonly available substances that can be fatal in withdrawal due to their propensity to induce withdrawal convulsions. Abrupt withdrawal from other drugs, such as opioids can cause an extremely physiologically and psychologically painful withdrawal that is very rarely fatal in patients of general good health and with medical treatment, but is more often fatal in patients with weakened cardiovascular systems; toxicity is generally caused by the often-extreme increases in heart rate and blood pressure (which can be treated with clonidine), or due to arrhythmia due to electrolyte imbalance caused by the inability to eat, and constant diarrhea and vomiting (which can be treated with loperamide and ondansetron respectively) associated with acute opioid withdrawal, especially in longer-acting substances where the diarrhea and emesis can continue unabated for weeks, although life-threatening complications are extremely rare, and nearly non-existent with proper medical management. Dependence itself and chronic intoxication on psychostimulants can cause mild-to-moderate neurotoxic effects due to hyperthermia and generation of free radicals.[4] This is treated with discontinuation; life-threatening complications are nonexistent.
Treatment
Treatment for physical dependence depends upon the drug being withdrawn and often includes administration of another drug, especially for substances that can be dangerous when abruptly discontinued. Physical dependence is usually managed by a slow dose reduction over a period of weeks, months or sometimes longer depending on the drug, dose and the individual.[3] A physical dependence on alcohol is often managed with a cross tolerant drug, such as long acting benzodiazepines to manage the alcohol withdrawal symptoms.
Drugs that cause physical dependence
- All µ-opioids with any (even slight) agonist effect, such as (partial list) morphine, heroin, codeine, oxycodone, buprenorphine, nalbuphine, methadone, and fentanyl, but not agonists specific to non-µ opioid receptors, such as salvinorin A (a k-opioid agonist), nor opioid antagonists or inverse agonists, such as naltrexone (a universal opioid inverse agonist)[5]
- All GABA agonists and positive allosteric modulators of both the GABA-A ionotropic receptor and GABA-B metabotropic receptor subunits, of which the following drugs are examples (partial list):
- alcohols such as ethyl alcohol (alcoholic beverage) (cf. alcohol dependence, alcohol withdrawal, delirium tremens)[6]
- barbiturates such as phenobarbital, sodium thiopental and secobarbital
- benzodiazepines such as diazepam (Valium), lorazepam (Ativan), and alprazolam (Xanax) (see benzodiazepine dependence and benzodiazepine withdrawal syndrome)
- nonbenzodiazepines (z-drugs) such as zopiclone and zolpidem.[7]
- gamma-hydroxybutyric acid (GHB) and 1,4-butanediol[8]
- carisoprodol (Soma) and related carbamates (tybamate and meprobamate)
- baclofen (Lioresal) and its non-chlorinated analogue phenibut
- chloral hydrate
- glutethimide
- clomethiazole
- methaqualone (Quaalude)
- gabapentin (Neurontin) and pregabalin (Lyrica), calcium channel modifiers that affect GABA[9]
- antiepileptic drugs such as valproate, lamotrigine, tiagabine, vigabatrin, carbamazepine and oxcarbazepine, and topiramate[9][10][11]
- possibly neuroleptic drugs such as clozapine, risperidone, olanzapine, haloperidol, thioridazine, etc.
- commonly prescribed antidepressants such as the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (cf. SSRI/SNRI withdrawal syndrome)[12][13][14]
- blood pressure medications, including beta blockers such as propanolol and alpha-adrenergic agonists such as clonidine[15][16]
- androgenic-anabolic steroids[17][18]
- glucocorticoids[19]
Rebound syndrome
A wide range of drugs whilst not causing a true physical dependence can still cause withdrawal symptoms or rebound effects during dosage reduction or especially abrupt or rapid withdrawal.[20] These can include caffeine,[21] stimulants,[22][23][24][25] steroidal drugs and antiparkinsonian drugs.[26] It is debated if the entire antipsychotic drug class causes true physical dependency, if only a subset does, or if none does,[27] but all, if discontinued too rapidly, cause an acute withdrawal syndrome.[28] When talking about illicit drugs rebound withdrawal is, especially with stimulants, sometimes referred to as "coming down" or "crashing".
Some drugs, like anticonvulsants and antidepressants, describe the drug category and not the mechanism. The individual agents and drug classes in the anticonvulsant drug category act at many different receptors and it is not possible to generalize their potential for physical dependence or incidence or severity of rebound syndrome as a group so need to be looked at individually. Anticonvulsants as a group however are known to cause tolerance to the anti-seizure effect.[29] SSRI drugs, which have an important use as antidepressants, are considered to cause physical dependence, although it is considered mild compared to drugs like opioids and GABA modulators, but they engender a discontinuation syndrome, which was originally called "SSRI withdrawal" until a 1997 symposium sponsored by Pfizer and Eli Lilly (the producers of several anti-depressants including Prozac and Effexor) was held, with the drug representative attendees concluding that "discontinuation syndrome" sounded less threatening than "withdrawal"; however, "SSRI discontinuation syndrome" is a withdrawal syndrome upon discontinuation of SSRI/SNRI drugs, just as "heroin discontinuation syndrome" is a synonym for "heroin withdrawal". Due to this, in Europe these drugs cannot be advertised as "non-habit forming".[citation needed] There have been case reports of dependence with venlafaxine (Effexor).[14]
See also
- Addiction
- Addiction recovery groups
- Alcohol withdrawal syndrome
- Benzodiazepine dependence
- Benzodiazepine withdrawal syndrome
- Discontinuation syndrome
- Drug and Alcohol Dependence
- Drug tolerance
- Rebound insomnia
- Substance dependence
References
- ^ "Definition of Udependence - NCI Dictionary of Cancer Terms". Retrieved 2008-12-21. [dead link]
- ^ "Drug Addiction". CNN.
{{cite news}}: Cite has empty unknown parameter:|coauthors=(help) [dead link] - ^ a b Landry MJ, Smith DE, McDuff DR, Baughman OL (1992). "Benzodiazepine dependence and withdrawal: identification and medical management". J Am Board Fam Pract. 5 (2): 167–75. PMID 1575069.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Sharma HS, Sjöquist PO, Ali SF (2007). "Drugs of abuse-induced hyperthermia, blood–brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51". Current pharmaceutical design. 13 (18): 1903–23. doi:10.2174/138161207780858375. PMID 17584116.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Trang T, Sutak M, Quirion R, Jhamandas K (May 2002). "The role of spinal neuropeptides and prostaglandins in opioid physical dependence". Br. J. Pharmacol. 136 (1): 37–48. doi:10.1038/sj.bjp.0704681. PMC 1762111. PMID 11976266.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Kozell L, Belknap JK, Hofstetter JR, Mayeda A, Buck KJ (July 2008). "Mapping a locus for alcohol physical dependence and associated withdrawal to a 1.1 Mb interval of mouse chromosome 1 syntenic with human chromosome 1q23.2-23.3". Genes, Brain and Behavior. 7 (5): 560–7. doi:10.1111/j.1601-183X.2008.00391.x. PMID 18363856.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Sikdar S; Ayonrinde, O.; Sampson, E. (July 1998). "Physical dependence on zopiclone. Prescribing this drug to addicts may give rise to iatrogenic drug misuse". BMJ. 317 (7151): 146. doi:10.1136/bmj.317.7151.146. PMC 1113504. PMID 9657802.
- ^ Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (January 1997). "Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence". Addiction. 92 (1): 89–96. doi:10.1111/j.1360-0443.1997.tb03640.x. PMID 9060200.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ a b Tran KT, Hranicky D, Lark T, Jacob Nj (June 2005). "Gabapentin withdrawal syndrome in the presence of a taper". Bipolar Disord. 7 (3): 302–4. doi:10.1111/j.1399-5618.2005.00200.x. PMID 15898970.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Hennessy MJ, Tighe MG, Binnie CD, Nashef L (November 2001). "Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep". Neurology. 57 (9): 1650–4. doi:10.1212/WNL.57.9.1650. PMID 11706106.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Lazarova M, Petkova B, Staneva-Stoycheva D (December 1999). "Effects of the calcium antagonists verapamil and nitrendipine on carbamazepine withdrawal". Methods Find Exp Clin Pharmacol. 21 (10): 669–71. doi:10.1358/mf.1999.21.10.795757. PMID 10702963.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Kora K, Kaplan P (2008). "[Hypomania/mania induced by cessation of antidepressant drugs]". Turk Psikiyatri Derg (in Turkish). 19 (3): 329–33. PMID 18791886.
- ^ Tint A, Haddad PM, Anderson IM (May 2008). "The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study". J. Psychopharmacol. (Oxford). 22 (3): 330–2. doi:10.1177/0269881107087488. PMID 18515448.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ a b Quaglio G, Schifano F, Lugoboni F (September 2008). "Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse". Addiction. 103 (9): 1572–4. doi:10.1111/j.1360-0443.2008.02266.x. PMID 18636997.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "MedlinePlus Medical Encyclopedia: Drug abuse and dependence". Retrieved 2008-12-21.
- ^ Karachalios GN, Charalabopoulos A, Papalimneou V; et al. (May 2005). "Withdrawal syndrome following cessation of antihypertensive drug therapy". Int. J. Clin. Pract. 59 (5): 562–70. doi:10.1111/j.1368-5031.2005.00520.x. PMID 15857353.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Trenton AJ, Currier GW (2005). "Behavioural manifestations of anabolic steroid use". CNS Drugs. 19 (7): 571–95. doi:10.2165/00023210-200519070-00002. PMID 15984895.
- ^ Hartgens F, Kuipers H (2004). "Effects of androgenic-anabolic steroids in athletes". Sports Med. 34 (8): 513–54. doi:10.2165/00007256-200434080-00003. PMID 15248788.
- ^ [1][dead link]
- ^ Heh CW, Sramek J, Herrera J, Costa J (July 1988). "Exacerbation of psychosis after discontinuation of carbamazepine treatment". Am J Psychiatry. 145 (7): 878–9. PMID 2898213.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Griffiths RR, Evans SM, Heishman SJ; et al. (December 1990). "Low-dose caffeine physical dependence in humans". J. Pharmacol. Exp. Ther. 255 (3): 1123–32. PMID 2262896.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Lake CR, Quirk RS (December 1984). "CNS stimulants and the look-alike drugs". Psychiatr. Clin. North Am. 7 (4): 689–701. PMID 6151645.
- ^ Sarampote CS, Efron LA, Robb AS, Pearl PL, Stein MA (2002). "Can stimulant rebound mimic pediatric bipolar disorder?". J Child Adolesc Psychopharmacol. 12 (1): 63–7. doi:10.1089/10445460252943588. PMID 12014597.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Danke F (1975). "[Methylphenidate addiction--Reversal of effect on withdrawal]". Psychiatr Clin (Basel) (in German). 8 (4): 201–11. PMID 1208893.
- ^ Cohen D, Leo J, Stanton T; et al. (2002). "A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study". Ethical Hum Sci Serv. 4 (3): 189–209. PMID 15278983.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Chichmanian RM, Gustovic P, Spreux A, Baldin B (1993). "[Risk related to withdrawal from non-psychotropic drugs]". Therapie (in French). 48 (5): 415–9. PMID 8146817.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Tierney, Lawrence M.; McPhee, Stephen J.; Papadakis, Maxine A. (2008). Current medical diagnosis & treatment, 2008. McGraw-Hill Medical. p. 916. ISBN 0-07-149430-8.
{{cite book}}: CS1 maint: multiple names: authors list (link) - ^ BNF (2008). "Antipsychotic drugs". UK: British National Formulary. Retrieved 22 december 2008.
{{cite web}}: Check date values in:|accessdate=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Wolfgang Löscher and Dieter Schmidt (August 2006). "Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs". Epilepsia. 47 (8): 1253–1284. doi:10.1111/j.1528-1167.2006.00607.x. PMID 16922870.